Makes the only monthly buprenorphine injection approved by the FDA for treating opioid addiction.
What stands out
- Earnings significantly exceed cash generation
At a glance
Makes the only monthly buprenorphine injection approved by the FDA for treating opioid addiction.
What this company is and how it runs — written from structure, not news.
Indivior makes SUBLOCADE, the only FDA-approved monthly buprenorphine injection, which slowly releases the drug over 28 days through a proprietary polymer matrix embedded directly into the manufacturing process at a DEA-registered facility. Because buprenorphine is a Schedule III controlled substance, the DEA sets a hard annual limit on how much Indivior can legally produce, so adding factory lines or capital does not raise the ceiling — only a federal rulemaking decision can do that. Clinics that adopt SUBLOCADE rebuild their entire patient-visit rhythm around monthly injections, training staff and setting monitoring schedules that do not work with daily pills or dissolving films, which means switching away requires a clinical overhaul rather than a simple prescription change. The whole business rests on holding both approvals at once — if the DEA cuts Indivior's quota or the FDA revokes the SUBLOCADE approval, the monthly injection format disappears entirely, because no other company currently has a comparable product cleared to take its place.
How does this company make money?
Indivior earns money each time a specialty pharmacy or opioid treatment program purchases a dose of SUBLOCADE or a SUBOXONE Film. SUBLOCADE injections bring in more revenue per unit than SUBOXONE films, because the extended-release polymer formulation is more complex to make and because clinics pay a premium for a product that keeps patients on a monthly schedule rather than relying on them to take a dose every day.
What makes this company hard to replace?
A clinic that wants to stop using SUBLOCADE cannot simply swap it for a different medication on their order sheet. Monthly injections require a different set of skills, appointment structures, and patient monitoring routines than daily pills or dissolving films placed under the tongue. Switching means retraining clinical staff and rebuilding those schedules from scratch. For patients, the change is also physical — someone stabilized on a 28-day injection cycle goes through an adjustment period when moved to a daily oral regimen, which creates medical risk during the transition.
What limits this company?
The DEA sets a hard annual limit on how much buprenorphine Indivior is allowed to produce. That limit comes from a federal rule-making process that has nothing to do with how big the factory is or how much money gets invested in it. When that quota is reached, production stops — regardless of how many patients still need the medication.
What does this company depend on?
Indivior cannot operate without four things it does not fully control: the DEA's ongoing registration that allows its facility to manufacture Schedule III controlled substances, the annual buprenorphine quota the DEA allocates to determine how much drug it can legally produce, the proprietary extended-release polymer matrices that make the 28-day formulation work, and continued FDA approval for both SUBLOCADE and SUBOXONE. It also relies on specialized distribution networks that are certified to handle Schedule III medications, because ordinary drug distributors are not legally permitted to ship them.
Who depends on this company?
Opioid treatment programs have built their monthly patient-visit schedules, staff training, and monitoring routines around SUBLOCADE. If the product disappeared, those clinics would have to convert patients to daily oral dosing — a different clinical process that requires retraining staff and puts patients through a physiological adjustment. Addiction medicine doctors who prescribe SUBOXONE Film would lose access to that specific naloxone-combination formulation and would have to switch patients to generic buprenorphine-naloxone products, which have different absorption profiles.
How does this company scale?
Once the polymer formulation is established, producing more SUBLOCADE doses uses standard pharmaceutical manufacturing steps that replicate relatively easily across production lines. What does not scale is the DEA quota — no matter how much manufacturing capacity Indivior adds, the annual government-set limit on buprenorphine production stays fixed, creating a ceiling that money alone cannot raise.
What external forces can significantly affect this company?
State Medicaid programs decide whether SUBLOCADE is covered for patients, and those decisions vary by state — many require a prior authorization process before a doctor can prescribe it, which can delay or block access. Federal opioid settlement funds flow to addiction treatment programs and influence which products those programs choose to use, meaning shifts in how that money is allocated can change purchasing decisions across many clinics at once.
Where is this company structurally vulnerable?
If the DEA cut Indivior's annual buprenorphine quota, production would shrink immediately — and no other company makes an FDA-approved monthly injection that could take its place. If the FDA withdrew approval for the SUBLOCADE New Drug Application, the product would have to come off the market entirely. Either event would leave patients who rely on monthly injections without any equivalent option.
Price is read as structure — trend, levels, range, peak and volatility drawn on the chart. It does not predict where price goes next.
Sign in to view price data.
Sign in1 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow is this stock behaving?
Three observations describe the present configuration: a high share of the trailing year's weekly closes were higher than the prior week, the company has reported positive net income in each of the last three annual periods, and the industry-benchmarked TTM operating cash flow margin is in the upper peer range.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
The reported statements, read against the company's own industry.
Shared structure with peers — never a ranking.
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Companies that share the same coordination system — how they create, deliver, or capture value.
Companies that share active interpretations — structural patterns currently present in both stocks.
CompanyGraph